COMPASS Pathways plc
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Business sectors
- biotechnology [1]
- Company / filing name
- COMPASS Pathways plc [2]
- Headquarters location
- London [1]
- Founded
- 2016-06-13 [1]
- Legal form
- public limited company [1]
- Official website
- compasspathways.com ↗ [1]
- ISIN (reported securities)
- US20451W1018 [1]
- CIK
- 1816590 [2]
- Country in background record
- United Kingdom [1]
- Symbols / exchanges
- CMPS (Nasdaq) [2]
Company positioning and business
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA). [3]
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD) New Drug Application (NDA), Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. [3]
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wallach's lab is said to have sought patents for over 200 novel compounds as of May 2024. [3]
Background text: Wikipedia contributors, Compass Pathways. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Financial year, securities and disclosures
Listed securities: CMPS (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [2]
History and key events
Founding / inception date recorded in Wikidata. [1]
Financial results and regulatory disclosures
No individual financial documents have been indexed yet. Open the source to consult company disclosures. [2]
Related entities and concepts
Frequently asked questions
When was COMPASS Pathways plc founded?
Founded: 2016-06-13. The linked source provides the background record. [1]
Where is the headquarters of COMPASS Pathways plc?
Headquarters location: London. The linked source provides the background record. [1]
Which business sectors are recorded for COMPASS Pathways plc?
Business sectors: biotechnology. The linked source provides the background record. [1]
Sources and review dates
- Wikidata — company background record (CC0) ↗
- Company identity and profile data ↗
- Wikipedia contributors — Compass Pathways (CC BY-SA 4.0) ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.